IL296075A - Combination therapy with neurogestat and targeted therapy-bcma and its uses - Google Patents

Combination therapy with neurogestat and targeted therapy-bcma and its uses

Info

Publication number
IL296075A
IL296075A IL296075A IL29607522A IL296075A IL 296075 A IL296075 A IL 296075A IL 296075 A IL296075 A IL 296075A IL 29607522 A IL29607522 A IL 29607522A IL 296075 A IL296075 A IL 296075A
Authority
IL
Israel
Prior art keywords
subject
bcma
nirogacestat
dihydrobromide
therapy
Prior art date
Application number
IL296075A
Other languages
English (en)
Hebrew (he)
Original Assignee
Springworks Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Springworks Therapeutics Inc filed Critical Springworks Therapeutics Inc
Publication of IL296075A publication Critical patent/IL296075A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001116—Receptors for cytokines
    • A61K39/001117—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR] or CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/804—Blood cells [leukemia, lymphoma]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
IL296075A 2020-03-13 2021-03-12 Combination therapy with neurogestat and targeted therapy-bcma and its uses IL296075A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062989372P 2020-03-13 2020-03-13
PCT/US2021/022177 WO2021183934A1 (en) 2020-03-13 2021-03-12 A combination therapy with nirogacestat and a bcma-directed therapy and uses thereof

Publications (1)

Publication Number Publication Date
IL296075A true IL296075A (en) 2022-11-01

Family

ID=75396879

Family Applications (1)

Application Number Title Priority Date Filing Date
IL296075A IL296075A (en) 2020-03-13 2021-03-12 Combination therapy with neurogestat and targeted therapy-bcma and its uses

Country Status (17)

Country Link
US (1) US20230121547A1 (enExample)
EP (1) EP4132515A1 (enExample)
JP (2) JP7781764B2 (enExample)
KR (1) KR20230009873A (enExample)
CN (1) CN115916188A (enExample)
AR (1) AR121566A1 (enExample)
AU (1) AU2021236340A1 (enExample)
BR (1) BR112022018251A2 (enExample)
CA (1) CA3171267A1 (enExample)
CL (1) CL2022002479A1 (enExample)
CO (1) CO2022014388A2 (enExample)
IL (1) IL296075A (enExample)
MX (1) MX2022011258A (enExample)
PE (1) PE20230614A1 (enExample)
TW (1) TW202200132A (enExample)
WO (1) WO2021183934A1 (enExample)
ZA (1) ZA202209989B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240056726A (ko) 2021-09-01 2024-04-30 스프링웍스 테라퓨틱스, 인크. 니로가세스타트의 합성
WO2023064872A1 (en) * 2021-10-14 2023-04-20 Precision Biosciences, Inc. Combinations of anti-bcma car t cells and gamma secretase inhibitors
CN118338900A (zh) * 2021-11-05 2024-07-12 斯普林渥克斯治疗有限公司 含尼罗加司他的组合物和治疗
AU2022396239A1 (en) * 2021-11-23 2024-06-06 Assia Chemical Industries Ltd. Solid state forms of nirogacestat salts
US12036207B2 (en) 2022-05-20 2024-07-16 Springworks Therapeutics, Inc. Treatments with nirogacestat
US12138246B2 (en) 2022-05-20 2024-11-12 Springworks Therapeutics, Inc. Treatments with nirogacestat
PE20250395A1 (es) 2022-05-20 2025-02-11 Springworks Therapeutics Inc Tratamientos con nirogacestat
US11951096B2 (en) 2022-05-20 2024-04-09 Springworks Therapeutics, Inc. Treatments with nirogacestat
CN120813574A (zh) * 2023-03-09 2025-10-17 苏州科睿思制药有限公司 尼罗司他二氢溴酸盐的晶型及其制备方法和用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10149855B2 (en) * 2014-02-05 2018-12-11 The Trustees Of Columbia University In The City Of New York Gamma-secretase inhibition reduce APOC3 levels and plasma triglycerides
HK1255694A1 (zh) * 2015-07-24 2019-08-23 Oncotracker, Inc. 用於治疗免疫系统功能障碍的γ分泌酶调节剂
WO2018151836A1 (en) * 2017-02-17 2018-08-23 Fred Hutchinson Cancer Research Center Combination therapies for treatment of bcma-related cancers and autoimmune disorders
EP3615055A1 (en) * 2017-04-28 2020-03-04 Novartis AG Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
US20200179511A1 (en) * 2017-04-28 2020-06-11 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
JP7050813B2 (ja) 2017-05-05 2022-04-08 華為技術有限公司 支援データ送信方法、デバイス、およびシステム
MX2020004568A (es) * 2017-11-06 2020-10-05 Juno Therapeutics Inc Combinación de una terapia celular y un inhibidor de gamma secretasa.
WO2019094626A1 (en) * 2017-11-08 2019-05-16 Fred Hutchinson Cancer Research Center Bispecific antibody compositions and related methods for improved pretargeted radioimunotherapies
TWI753229B (zh) * 2018-01-17 2022-01-21 美商明塞特製藥公司 用於治療癌症之組合療法
KR20210013184A (ko) * 2018-05-24 2021-02-03 아얄라 파마큐티컬즈 아이엔씨. 비스플루오로알킬-1,4-벤조디아제피논 화합물과 면역요법제를 포함하는 조성물 및 이의 사용 방법
EP3802611A2 (en) * 2018-06-01 2021-04-14 Novartis AG Binding molecules against bcma and uses thereof
US20220168417A1 (en) * 2019-04-10 2022-06-02 Glaxosmithkline Intellectual Property Development Limited Combination therapy with an anti bcma antibody and a gamma secretase inhibitor
WO2021029854A1 (en) * 2019-08-09 2021-02-18 Pfizer Inc. Solid state forms of (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide and uses thereof

Also Published As

Publication number Publication date
JP2023517243A (ja) 2023-04-24
CL2022002479A1 (es) 2023-08-18
BR112022018251A2 (pt) 2022-11-08
WO2021183934A1 (en) 2021-09-16
KR20230009873A (ko) 2023-01-17
AU2021236340A1 (en) 2022-09-29
JP7781764B2 (ja) 2025-12-08
PE20230614A1 (es) 2023-04-14
US20230121547A1 (en) 2023-04-20
CO2022014388A2 (es) 2023-02-16
JP2025168430A (ja) 2025-11-07
EP4132515A1 (en) 2023-02-15
AR121566A1 (es) 2022-06-15
TW202200132A (zh) 2022-01-01
CN115916188A (zh) 2023-04-04
ZA202209989B (en) 2025-12-17
CA3171267A1 (en) 2021-09-16
MX2022011258A (es) 2023-01-11

Similar Documents

Publication Publication Date Title
IL296075A (en) Combination therapy with neurogestat and targeted therapy-bcma and its uses
US12377054B2 (en) Targeting the innate immune system to induce long-term tolerance and to resolve macrophage accumulation in atherosclerosis
IL263245A (en) Method for the treatment of liver failure
IL281344B1 (en) Combination of ADAGRASIB and CETUXIMAB for cancer treatment
NZ578621A (en) Use of sodium meta arsenite compounds for treatment of pain and inflammation
IL278281B2 (en) Crystalline form of C–MET inhibitor and its salt form and method for preparing them
CA3198202A1 (en) Methods for treating cancer
WO2021170078A1 (zh) 一种csf-1r激酶抑制剂的用途
IL292005B2 (en) Solid-state crystalline forms of N-[4-(6-fluoro-3,4-dihydro-H1-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide
IL297839A (en) Polymorphs of pyrimidine cyclohexyl glucocorticoid receptor modulators
IL251136B (en) Combination therapy of inhibitors of c-c chemokine receptor type 9 (ccr9) and anti-alha4beta7 integrin blocking antibodies
IL304920A (en) A voltage-gated potassium channel opener for use in the treatment of anhedonia
WO2025044424A1 (zh) 一种基于免疫检查点阻断的抗肿瘤药物组合物及其应用
IL256662A (en) Focusidase inhibitors
IL291979A (en) Phospholipid-flaveglin conjugates and methods of using them for targeted cancer therapy
IL313052A (en) Methods of using rarγ agonists for cancer treatment
IL311497A (en) Use of an antibody-drug conjugate, and a combined drug and its use
IL280831B1 (en) Combination therapy using c-c chemokine receptor 4 (ccr4) antagonists and one or more immune checkpoint inhibitors
CA3211860A1 (en) Enamine n-oxides: synthesis and application to hypoxia-responsive prodrugs and imaging agents
US20080004272A1 (en) Compositions and methods for modulating gated ion channels
IL297640A (en) Methods and combinations for cancer treatment using immune checkpoint inhibitor antibodies
IL278596B1 (en) RAS oncoprotein inhibitors, methods for preparing and methods for using them
CN115068478A (zh) 磷酸萘酚喹在制备治疗自身免疫性疾病药物中的应用
Liu et al. The RIP3 activator C8 regulates the autophagy flux mediated by p62 and promotes the immunogenic form of cell death in human gastric cancer cells
IL299755A (en) A pharmaceutical preparation for the prevention or treatment of cancer that contains a naphthoquinone-based compound and inhibits an immune checkpoint as active ingredients